{"acquisitions":[],"changes":[],"country":"US","description":"Life Biosciences develops partial epigenetic reprogramming therapies that revert aged cells to a younger functional state for age-related disease. It targets patients with optic neuropathies and liver disease first, expanding to broader aging conditions. Lead candidate ER-100 cleared FDA investigational use in January 2026, targeting causes rather than symptoms.","domain":"lifebiosciences.com","employees":null,"founded":2016,"fundingTotalQuarantined":false,"githubOrg":"unknown","githubStars":null,"industry":"unknown","industrySources":[],"investors":[],"lat":42.358834,"lng":-71.05783,"location":"Boston, United States","multiples":[],"name":"Life Biosciences","people":[],"revenues":[],"rounds":[{"amountQuarantined":false,"amountUsd":80000000,"connectionsAmong":[],"currency":"USD","date":"2026-04-01","investments":[],"investors":[],"leadInvestor":null,"leadInvestors":[],"people":[],"slug":"lifebiosciences-com-2026-04-01-series-b","source":{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-05-25","status":"attributed","url":null},"status":"attributed","type":"series-d+","url":null}],"slug":"lifebiosciences-com","sources":[{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-05-25","status":"attributed","url":null},{"fact":"existence","publisher":"lifebiosciences.com","retrievedAt":"2026-05-25","status":"self-reported","url":"https://lifebiosciences.com"},{"fact":"description","publisher":"lifebiosciences.com","retrievedAt":"2026-05-25","status":"self-reported","url":"https://lifebiosciences.com"}],"stage":"series-b+","stockCard":{"asOf":"2026-11-09","facts":[],"generatedAt":"2026-11-09","state":"insufficient-evidence","tldr":[]},"techStack":["unknown"],"totalRaisedUsd":150000000,"traction":[],"updatedAt":"2026-05-25","valuations":[]}